Shen S, DeNardo G L, Sgouros G, O'Donnell R T, DeNardo S J
Division of Hematology/Oncology, University of California Davis Medical Center, Sacramento 95816, USA.
J Nucl Med. 1999 Dec;40(12):2102-6.
Accurate determination of red marrow radiation is important because myelotoxicity is often dose limiting in radioimmunotherapy. The S-value methodology assumes a fixed red marrow mass as defined by the standard Medical Internal Radiation Dose (MIRD) mathematic phantom. Substantial error can be introduced in marrow radiation estimates because red marrow mass varies from patient to patient. In this work we describe a patient-specific marrow dosimetry methodology that does not require an explicit estimate of marrow mass.
Photon radiation to marrow from all sources can be considered as the total body to marrow. Based on photon radiation from body and electron radiation from blood, a patient-specific marrow dose can be determined by counting blood and total body radioactivity and measuring body weight.
The deviation in marrow dose calculation using total body to represent all photon radiation was 3.9% in 66 patients administered 131I-labeled antibodies and was 9.1% in 18 patients administered 67Cu-labeled antibodies. The differences between this patient-specific approach and estimates based on standard anatomy were considerable, ranging from -35% to 88%. The differences were greater when patients' weights differed substantially from the MIRD reference man phantom.
For radiopharmaceuticals that do not bind marrow, patient-specific marrow dosimetry can be independent of the actual marrow mass of a patient. Patient-specific marrow dosimetry can be determined using radioactivity concentration in blood and body.
准确测定红骨髓辐射很重要,因为在放射免疫治疗中骨髓毒性通常是剂量限制因素。S值方法假定红骨髓质量固定,由标准医学内照射剂量(MIRD)数学模型定义。由于不同患者的红骨髓质量不同,在骨髓辐射估计中可能会引入大量误差。在这项工作中,我们描述了一种无需明确估计骨髓质量的针对患者个体的骨髓剂量测定方法。
来自所有源的光子对骨髓的辐射可视为全身对骨髓的辐射。基于身体的光子辐射和血液的电子辐射,通过计数血液和全身放射性并测量体重,可以确定针对患者个体的骨髓剂量。
在接受131I标记抗体治疗的66例患者中,使用全身来代表所有光子辐射进行骨髓剂量计算的偏差为3.9%,在接受67Cu标记抗体治疗的18例患者中为9.1%。这种针对患者个体的方法与基于标准解剖学的估计之间的差异相当大,范围从-35%到88%。当患者体重与MIRD参考人体模型有很大差异时,差异更大。
对于不结合骨髓的放射性药物,针对患者个体的骨髓剂量测定可以独立于患者的实际骨髓质量。可以使用血液和身体中的放射性浓度来确定针对患者个体的骨髓剂量。